JACC. Case reports · 2026
Transcatheter Tricuspid Valve Replacement in Rheumatic Tricuspid Valve Regurgitation.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yang Jessica, Tang Gilbert H L, Lerakis Stamatios, Onishi Takayuki, Kini Annapoorna S, Khera Sahil, Safi Lucy M
Аннотация
BACKGROUND: Rheumatic heart disease (RHD) is a leading cause of valvular heart disease worldwide, particularly in developing countries. The mitral and aortic valves are most often affected; however, tricuspid valve involvement has been observed in advanced cases.
CASE SUMMARY: We present a case of a patient with RHD with tricuspid valve involvement who successfully underwent transcatheter tricuspid valve replacement (TTVR).
DISCUSSION: TTVR is a promising, less-invasive alternative treatment for patients with severe symptomatic tricuspid regurgitation deemed unsuitable for surgery. Despite the increasing adoption of TTVR, patients with RHD are frequently excluded from major clinical trials, leading to limited evidence supporting the use of this intervention in this population.
TAKE-HOME MESSAGES: As TTVR technology advances, its application in RHD warrants further exploration. The routine exclusion of RHD patients or pathology from TTVR clinical trials should also be reconsidered.
CASE SUMMARY: We present a case of a patient with RHD with tricuspid valve involvement who successfully underwent transcatheter tricuspid valve replacement (TTVR).
DISCUSSION: TTVR is a promising, less-invasive alternative treatment for patients with severe symptomatic tricuspid regurgitation deemed unsuitable for surgery. Despite the increasing adoption of TTVR, patients with RHD are frequently excluded from major clinical trials, leading to limited evidence supporting the use of this intervention in this population.
TAKE-HOME MESSAGES: As TTVR technology advances, its application in RHD warrants further exploration. The routine exclusion of RHD patients or pathology from TTVR clinical trials should also be reconsidered.